$2.01
+0.00 (+0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TXMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 3 with posted results
Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| The Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl EstradiolNCT04272008The effect of Annovera and tampon co-use on area-under-the-curve (AUC) of Segesterone acetate and ethinyl estradiol (Days 2 to 3)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Segesterone Acetate and Ethinyl Estradiol · Other: Tampon | Contraception | 21 | 2021-06-08actual | 2021-10-29 |
| Annovera™ Drug-Drug Interaction StudyNCT04290390Area-under-the-curve (AUC) of rifampin and itraconzaole on Annovera (segesterone acetate and ethinyl estradiol)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Segesterone Acetate and Ethinyl Estradiol, Rifampin, Itraconazole | Women, Contraception | 67 | 2021-01-06actual | 2021-01-29 |
| A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor SymptomsNCT01942668results2019-05-06Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Estradiol, Progesterone, Placebo | Menopause | 1,845 | 2016-10-28actual | 2019-05-06 |
| Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal WomenNCT02253173results2017-05-25Co-Primary Efficacy Endpoint - Vaginal Superficial CellsRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Estradiol, Placebo | Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse | 764 | Oct 2015actual | 2017-05-25 |
| A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary AmenorrheaNCT02019589• The proportion of subjects at Cycle 3 Day 24 ± 1 day on active treatment compared to placebo with complete secretory activity on endometrial biopsy.Randomized · Triple-masked · Treatment | Phase 3 | Terminated | Drug: Progesterone, Placebo | Secondary Amenorrhea | 6 | 2014-10-31actual | 2018-05-08 |
| TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal AtrophyNCT02449902results2015-12-14Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Estradiol, placebo | Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia | 50 | Sep 2013actual | 2015-12-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19